跳到正文
原文
Nature 健康护理主题·· 2026-10-12AI 评分57

回顾性分析提示固定ARR阈值可能低估年轻高血压患者的原发性醛固酮增多症

Potential under-recognition of primary aldosteronism in young adults with hypertension

AI 导读

一项纳入14750例高血压患者的回顾性分析显示,在确诊原发性醛固酮增多症的患者中,基线ARR低于20的比例随年龄降低而升高,<35岁组为57.5%,≥55岁组为33.2%。

正文
  • Article
  • Published: 12 October 2026

Journal of Human Hypertension (2026) Cite this article

Abstract

The aldosterone-to-renin ratio (ARR) is the primary screening test for primary aldosteronism (PA), but it is strongly influenced by renin activity, which varies with age. Fixed ARR thresholds may therefore under-recognize PA in younger adults. We retrospectively analyzed 14,750 hypertensive patients who underwent saline infusion testing for suspected PA. An ARR of 20 was consistently used as the local reference threshold, but confirmatory testing could proceed despite ARR < 20 when clinical suspicion was high. Baseline plasma renin activity (PRA), aldosterone concentration (ALD), and ARR were measured before saline infusion. Of 13,428 patients with calculable ARR, 8703 (64.8%) underwent saline infusion testing despite ARR < 20, and 1578 had confirmed PA. Among 3966 confirmed PA patients with classifiable age-ARR data, ARR < 20 occurred in 57.5, 50.6, 35.4, and 33.2% of patients aged <35, 35–44, 45–54, and ≥55 years, respectively. Increasing age remained associated with lower odds of ARR < 20 after adjustment for sex, body mass index, blood pressure, potassium, creatinine, and a documented adrenal nodule (adjusted OR per year, 0.975; 95% CI, 0.967–0.984). The gradient persisted after restricting analyses to patients without a documented adrenal nodule, with potassium ≥3.5 mmol/L and eGFR ≥60 mL/min/1.73 m². Younger adults with confirmed PA frequently had baseline ARR values below 20, largely with relatively preserved PRA. Although residual referral bias cannot be excluded, these findings support cautious, age-informed interpretation of ALD, PRA, and ARR.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Subscribe to this journal

Receive 12 digital issues and online access to articles

111,21 € per year

only 9,27 € per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Data availability

The individual-level data used in this study are currently not publicly available due to ethical restrictions on sharing participant data.

References

  1. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 ;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4

    Article  CAS  PubMed  Google Scholar 

  2. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021 ;9:876–92. https://doi.org/10.1016/s2213-8587(21)00210-2

    Article  PubMed  Google Scholar 

  3. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020 ;173:10–20. https://doi.org/10.7326/M20-0065

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wannachalee T, Lieberman L, Turcu AF. High prevalence of autonomous aldosterone production in hypertension: how to identify and treat it. Curr Hypertens Rep. 2022 ;24:123–32. https://doi.org/10.1007/s11906-022-01176-7

    Article  CAS  PubMed  Google Scholar 

  5. Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2025 ;110:2453–95. https://doi.org/10.1210/clinem/dgaf284

    Article  CAS  PubMed  Google Scholar 

  6. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016 ;101:1889–916. https://doi.org/10.1210/jc.2015-4061

    Article  CAS  PubMed  Google Scholar 

  7. Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, et al. Screening rates for primary aldosteronism in resistant hypertension: A Cohort Study. Hypertension. 2020 ;75:650–9. https://doi.org/10.1161/hypertensionaha.119.14359

    Article  CAS  PubMed  Google Scholar 

  8. Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with apparent treatment-resistant hypertension: retrospective analysis of current practice. Endocr Pract. 2022 ;28:271–5. https://doi.org/10.1016/j.eprac.2021.11.085

    Article  PubMed  Google Scholar 

  9. Kao TW, Chen JY, Liu JH, Tseng WH, Hsieh CC, Wu VC, et al. Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis. Ther Adv Endocrinol Metab. 2024 ;15:20420188241303429. https://doi.org/10.1177/20420188241303429

    Article  PubMed  PubMed Central  Google Scholar 

  10. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012 ;44:170–6. https://doi.org/10.1055/s-0031-1295460

    Article  CAS  PubMed  Google Scholar 

  11. Bauer JH. Age-related changes in the renin-aldosterone system. physiological effects and clinical implications. Drugs Aging. 1993 ;3:238–45. https://doi.org/10.2165/00002512-199303030-00005

    Article  CAS  PubMed  Google Scholar 

  12. Belmin J, Lévy BI, Michel JB. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging. 1994 ;5:391–400. https://doi.org/10.2165/00002512-199405050-00007

    Article  CAS  PubMed  Google Scholar 

  13. Zhang C, Guo Z, Yi C, Wang H, Zhang W, Zhao Y. Age- and sex-specific reference intervals for renin and aldosterone in healthy individuals in Yunnan Province, China. J Hum Hypertens. 2025 ;39:652–7. https://doi.org/10.1038/s41371-025-01006-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Variability of aldosterone, renin and the aldosterone-to-renin ratio in hypertensive patients without primary aldosteronism. J Hypertens. 2022 ;40:2256–62. https://doi.org/10.1097/hjh.0000000000003257

    Article  CAS  PubMed  Google Scholar 

  15. Nakama C, Kamide K, Kawai T, Hongyo K, Ito N, Onishi M, et al. The influence of aging on the diagnosis of primary aldosteronism. Hypertension Res. 2014 ;37:1062–7. https://doi.org/10.1038/hr.2014.129

    Article  CAS  Google Scholar 

  16. Nwia SM, Leite APO, Li XC, Zhuo JL. Sex differences in the renin-angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and kidney diseases. Front Cardiovasc Med. 2023 ;10:1198090. https://doi.org/10.3389/fcvm.2023.1198090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. de Freminville JB, Gardini M, Cremer A, Camelli S, Baron S, Bobrie G, et al. Prevalence and risk factors for secondary hypertension in young adults. Hypertension. 2024 ;81:2340–9. https://doi.org/10.1161/hypertensionaha.124.22753

    Article  PubMed  Google Scholar 

  18. Jehpsson L, Sun J, Nilsson PM, Edsfeldt A, Swärd P. Serum renin levels increase with age in boys resulting in higher renin levels in young men compared to young women, and soluble angiotensin-converting enzyme 2 correlates with renin and body mass index. Front Physiol. 2020 ;11:622179. https://doi.org/10.3389/fphys.2020.622179

    Article  PubMed  Google Scholar 

  19. Ng E, Gwini SM, Libianto R, Choy KW, Lu ZX, Shen J, et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J Clin Endocrinol Metab. 2022 ;108:33–41. https://doi.org/10.1210/clinem/dgac568

    Article  PubMed  Google Scholar 

  20. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 ;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339

    Article  PubMed  Google Scholar 

Download references

Funding

This study was funded by the Major Science and Technology Projects of Xinjiang Uygur Autonomous Region (2022A03012-5).

Author information

Author notes

  1. These authors contributed equally: Jianwen Zhao, Delian Zhang.

Authors and Affiliations

  1. Hypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region; Xinjiang Hypertension Institute; NHC Key Laboratory of Hypertension Clinical Research; Key Laboratory of Xinjiang Uygur Autonomous Region “Hypertension Research Laboratory”; Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China

    Jianwen Zhao, Delian Zhang, Junli Hu, Qing Zhu, Jing Hong, Saimire Anwaier, Qin Luo & Nanfang Li

Authors

  1. Jianwen Zhao
  2. Delian Zhang
  3. Junli Hu
  4. Qing Zhu
  5. Jing Hong
  6. Saimire Anwaier
  7. Qin Luo
  8. Nanfang Li

Contributions

Jianwen Zhao and Delian Zhang drafted the manuscript. Jianwen Zhao and Qin Luo performed the statistical analyses. Junli Hu extracted clinical data and curated the dataset; Qing Zhu reviewed clinical records and validated the data; Jing Hong collected laboratory data and processed samples; and Saimire Anwaier collected clinical data and verified the dataset. Nanfang Li acquired funding and supervised the study.

Corresponding author

Correspondence to Nanfang Li.

Ethics declarations

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the People’s Hospital of Xinjiang Uygur Autonomous Region (approval no. KY2026092901). All participants provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Consent for publication Not applicable. No identifiable images or individual participant details are included.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, J., Zhang, D., Hu, J. et al. Potential under-recognition of primary aldosteronism in young adults with hypertension. J Hum Hypertens (2026). https://doi.org/10.1038/s41371-026-01245-3

Download citation

  • Received: 24 May 2026

  • Revised: 16 September 2026

  • Accepted: 06 October 2026

  • Published: 12 October 2026

  • Version of record: 12 October 2026

  • DOI: https://doi.org/10.1038/s41371-026-01245-3

来源:Nature 健康护理主题 · nature.com